The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease

E. D. Bateman, D. Singh, P. W. Jones, A. Agusti, R. Lamarca, G. de Miquel, C. Caracta, E. Garcia Gil (Cape Town, South Africa; Manchester, London, United Kingdom; Barcelona, Spain; , United States Of America)

Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Session: Airways disease comorbidities and general aspects
Session type: Thematic Poster Session
Number: 4005
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. D. Bateman, D. Singh, P. W. Jones, A. Agusti, R. Lamarca, G. de Miquel, C. Caracta, E. Garcia Gil (Cape Town, South Africa; Manchester, London, United Kingdom; Barcelona, Spain; , United States Of America). The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease. Eur Respir J 2011; 38: Suppl. 55, 4005

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011


Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011


Efficacy of tiotropium bromide in patients with chronic obstructive pulmonary disease of varying severity
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008


Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014


Evaluation of the efficacy and safety of two formulations of Ipratropium bromide HFA pMDI in patients with mild to moderate chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2010 - COPD: treatment and monitoring
Year: 2010

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Source: Eur Respir J 2003; 21: 912
Year: 2003


Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 74-81
Year: 2003



Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011


Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010


Modelling the 5-year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease (COPD) in Spain
Source: Eur Respir J 2006; 28: Suppl. 50, 683s
Year: 2006

One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 23: 241-249
Year: 2004



Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
Source: Eur Respir J 2012; 40: 1106-1114
Year: 2012



Comparative study of two years treatment with salmeterol alone and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2004; 24: Suppl. 48, 342s
Year: 2004

Efficacy of budesonide/formoterol in Chinese patients with chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD
Source: Eur Respir J 2011; 38: 797-803
Year: 2011



A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 217-224
Year: 2002



Once-daily QVA149 has a good safety profile in patients with COPD
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial
Source: Eur Respir J 2002; 19: 936-943
Year: 2002



ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013